Grebely J, Matthews S, Causer LM, Feld JJ, Cunningham P, Dore GJ, Applegate TL. We have reached single-visit testing, diagnosis, and treatment for hepatitis C
Pol S, Thompson A, Collins M, Venier E, Cotte L, Laguno Centeno M, et al. Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the
Grishma H, Bettina H, Chien-Hung C et al, on behalf of the RETRACT-B study group. Am J Gastroenterol, 2024 DOI: 10.14309/ajg.0000000000002759 Πατώντας ΕΔΩ μπορείτε να
Wang B, Zhou J, Wu X, Sun Y, Li L, Li P, et al. Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression:
Semmler G, Alonso lópez S, Pons M, Lens S, Dajti E, Griemsmann M, et al. Published: March 21, 2024, Journal of Hepatology DOI: https://doi.org/10.1016/j.jhep.2024.03.015 Πατώντας
Lee MH, Chen YT, Huang YH, Yang HI, Chen HY, Chen CJ, et al Published: February 16, 2024 DOI:https://doi.org/10.1016/j.cgh.2024.01.045 Πατώντας ΕΔΩ μπορείτε να δείτε την
Zhang Y, Liu X, Li S, Lin C, Ye Q, Wang Y, et al. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation:
Lu M, Salgia R, Li J, et al. Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat 2023;30:746–755. DOI:
Huang D, Tran A, Yeh ML, Yasuda S, Tsai PC, Pei-Chien H, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis
Chun HS, Papatheodoridis GV, Lee M, Lee HA, Kim YH, Kim SH, Oh YS, Park SJ, Kim J, Lee HA, Kim HY, Kim TH, Yoon